A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

Trial Details

NCT ID

NCT06797297

Phase

PHASE2

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Status

RECRUITING

Cancer Type

Mucosal Melanoma Melanoma

Interventions

• IBI363
• Pembrolizumab

Locations (sample)

• Hefei, Anhui, China|31.86389,117.28083
• Beijing, Beijing Municipality, China|39.9075,116.39723
• Beijing, Beijing Municipality, China|39.9075,116.39723
• Chongqing, Chongqing Municipality, China|29.56026,106.55771
• Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

• Histologically or cytologically confirmed unresectable, locally advanced or metastatic mucosal or acral-type melanoma, according to the American Jo…
• No prior systemic treatment for unresectable or metastatic melanoma; Prior adjuvant or neoadjuvant therapy (except for disease progression to unres…
• Have at least one measurable lesion (target lesion) according to RECIST v1.1. For lesions that have previously received radiotherapy or intratumora…
• The target lesions of this study must be measured by imaging (enhanced CT or MRI. Plain scan CT or MRI can be accepted after communication with the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.